![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
P Savi, MC Laplace, JP Maffrand and JM Herbert
Sanofi Recherche, Toulouse, France.
Thienopyridine compounds, including ticlopidine and clopidogrel, have been found to selectively inhibit adenosine 5' diphosphate (ADP)- induced platelet aggregation and adenylyl cyclase ex vivo, but the mechanism of their antiplatelet action remains to be determined. This study was aimed at investigating the effect of clopidogrel and ticlopidine on the binding of [3H]-2-methylthio- adenosine-5'- diphosphate (2-MeS-ADP) to rat platelets. Binding of [3H]-2-MeS-ADP to rat platelets was time-dependent and saturable. Scatchard analysis of the saturation binding data indicated that [3H]-2-MeS-ADP bound to one population of specific binding sites with high affinity (KD = 0.78 +/- 0.05 nM; Bmax = 156.3 +/- 4.8 fmole/10(8) cells) (n = 3). Unlabeled 2- MeS-ADP and ADP competitively and selectively inhibited the specific binding of [3H]-2-MeS-ADP with IC50 values of 11.3 +/- 1.2 nM and 11.3 +/- 0.7 microM, respectively (n = 3). Other nucleotide analogs such as ADP-beta S, ATP and ATP-alpha S also antagonized [3H]-2-MeS-ADP binding. When administered orally at doses ranging from 1 to 25 mg/kg, clopidogrel inhibited ADP- or 2-MeS-ADP-induced platelet aggregation as well as ADP or 2-MeS-ADP-induced inhibition of intraplatelet adenylyl cyclase. When measured in parallel, clopidogrel reduced in a dose- dependent manner the binding of [3H]-2-MeS-ADP to rat platelets ex vivo. Clopidogrel administration resulted in the decrease of [3H]-2-MeS- ADP binding sites on platelets without any significant change in the affinity; this indicates noncompetitive binding. Ticlopidine (200 mg/kg a day for 3 days) behaved in the same way.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  S. Ziegler, M. Schillinger, M. Funk, K. Felber, M. Exner, W. Mlekusch, S. Sabeti, J. Amighi, E. Minar, M. Brunner, et al. Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12, and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease Stroke, July 1, 2005; 36(7): 1394 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mudaliar Intense Management of Diabetes Mellitus: Role of Glucose Control and Antiplatelet Agents J. Clin. Pharmacol., April 1, 2004; 44(4): 414 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kim, J. Jin, and S. P. Kunapuli Akt Activation in Platelets Depends on Gi Signaling Pathways J. Biol. Chem., February 6, 2004; 279(6): 4186 - 4195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Marteau, E. Le Poul, D. Communi, D. Communi, C. Labouret, P. Savi, J.-M. Boeynaems, and N. S. Gonzalez Pharmacological Characterization of the Human P2Y13 Receptor Mol. Pharmacol., July 1, 2003; 64(1): 104 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Pereillo, M. Maftouh, A. Andrieu, M.-F. Uzabiaga, O. Fedeli, P. Savi, M. Pascal, J.-M. Herbert, J.-P. Maffrand, and C. Picard Structure and Stereochemistry of the Active Metabolite of Clopidogrel Drug Metab. Dispos., November 1, 2002; 30(11): 1288 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Fihn, S. V. Williams, J. Daley, and R. J. Gibbons Guidelines for the Management of Patients with Chronic Stable Angina: Treatment Ann Intern Med, October 16, 2001; 135(8_Part_1): 616 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Gibbons, K. Chatterjee, J. Daley, J. S. Douglas, S. D. Fihn, J. M. Gardin, M. A. Grunwald, D. Levy, B. W. Lytle, R. A. O'Rourke, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina) J. Am. Coll. Cardiol., June 1, 1999; 33(7): 2092 - 2197. [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Harker, U. M. Marzec, A. B. Kelly, N. R. F. Chronos, I. B. Sundell, S. R. Hanson, and J.-M. Herbert Clopidogrel Inhibition of Stent, Graft, and Vascular Thrombogenesis With Antithrombotic Enhancement by Aspirin in Nonhuman Primates Circulation, December 1, 1998; 98(22): 2461 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hechler, C. Leon, C. Vial, P. Vigne, C. Frelin, J.-P. Cazenave, and C. Gachet The P2Y1 Receptor Is Necessary for Adenosine 5'-Diphosphate-Induced Platelet Aggregation Blood, July 1, 1998; 92(1): 152 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, N. Kleiman, J. J. Ferguson, J. P. Runyon, T. M. Broderick, N. A. Higby, L. H. Martin, G. Hantsbarger, S. McDonald, and R. J. Anders Sustained Platelet Glycoprotein IIb/IIIa Blockade With Oral Xemilofiban in 170 Patients After Coronary Stent Deployment Circulation, August 19, 1997; 96(4): 1117 - 1121. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Humbert, P. Nurden, C. Bihour, J.-M. Pasquet, J. Winckler, E. Heilmann, P. Savi, J.-M. Herbert, T. J. Kunicki, and A. T. Nurden Ultrastructural Studies of Platelet Aggregates From Human Subjects Receiving Clopidogrel and From a Patient With an Inherited Defect of an ADP-Dependent Pathway of Platelet Activation Arterioscler. Thromb. Vasc. Biol., December 1, 1996; 16(12): 1532 - 1543. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Savi, E. Heilmann, P. Nurden, M.-C. Laplace, C. Bihour, G. Kieffer, A. T. Nurden, and J.-M. Herbert Clopidogrel: An Antithrombotic Drug Acting on the ADP-dependent Activation Pathway of Human Platelets Clinical and Applied Thrombosis/Hemostasis, January 1, 1996; 2(1): 35 - 42. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
